DrugPatentWatch Database Preview
Exelixis Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are seven US patents protecting EXELIXIS drugs.
There are one hundred and seventy patent family members on EXELIXIS drugs in twenty-nine countries and seventeen supplementary protection certificates in fourteen countries.
Summary for Exelixis
| International Patents: | 170 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
| Patent Litigation for Exelixis: | See patent lawsuits for Exelixis |
Drugs and US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 9,724,342 | Start Trial | Y | Start Trial | |||
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | No | 7,579,473 | Start Trial | Y | Y | Start Trial | ||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I619495 | Start Trial |
| Eurasian Patent Organization | 201391145 | Start Trial |
| Croatia | P20110707 | Start Trial |
| Croatia | P20130458 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 43/2014 | Austria | Start Trial | PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326 |
| 2213661 | 1490053-4 | Sweden | Start Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326 |
| 2213661 | PA2014033 | Lithuania | Start Trial | PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321 |
| 2213661 | 300678 | Netherlands | Start Trial | PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
